Gilder Gagnon Howe & Co’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,028	Closed	-$388K	–	362
2020 Q3	$388K	Sell	7,028 -22	-0.3%	-$1.4K	﹤0.01%	284
2020 Q2	$445K	Buy	7,050 +7,037	+54,131%	+$483K	﹤0.01%	254
2020 Q1	$1K	Sell	13 -51,742	-100%	-$3.47M	﹤0.01%	280
2019 Q4	$4.11M	Buy	+51,755	New	+$3.07M	0.04%	178
2018 Q1	–	Sell	-8,854	Closed	-$348K	–	308
2017 Q4	$348K	Sell	8,854 -279	-3%	-$10.4K	﹤0.01%	250
2017 Q3	$284K	Sell	9,133 -37	-0.4%	-$1.04K	﹤0.01%	241
2017 Q2	$251K	Sell	9,170 -180	-2%	-$5.36K	﹤0.01%	238
2017 Q1	$345K	Buy	+9,350	New	+$235K	0.01%	223
2016 Q1	–	Sell	-297,053	Closed	-$9.6M	–	264
2015 Q4	$9.6M	Buy	+297,053	New	+$12.9M	0.15%	96

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gilder Gagnon Howe & Co's GBT Position: Q4 2020 in Review

Gilder Gagnon Howe & Co sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 7,028 shares — an estimated $388K sold.

Gilder Gagnon Howe & Co first reported a position in GBT in Q4 2015 and held it in 9 quarters. The position peaked at $9.6M in Q4 2015. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Gilder Gagnon Howe & Co reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 7,028 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $388K.
Gilder Gagnon Howe & Co first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
Gilder Gagnon Howe & Co's Global Blood Therapeutics, Inc. position peaked at $9.6M in Q4 2015.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2020, filed 16 Feb 2021.